Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Iovance Biotherapeutics, MaSTherCell Enter Mfg. Pact | Contract Pharma

What are you searching for?

Sign in
Breaking News

Iovance Biotherapeutics, MaSTherCell Enter Mfg. Pact

MaSTherCell will manufacture TIL for Iovance’s late-stage clinical trials

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Iovance Biotherapeutics, a biotechnology company developing cancer immunotherapies, and MaSTherCell S.A., a cell therapy CDMO, have entered into a new three-year manufacturing services agreement under which MaSTherCell will manufacture TIL for Iovance’s late-stage clinical trials at its commercial-ready cGMP manufacturing suites. 
 
“We are pleased to be expanding our clinical and manufacturing capacity in Europe through this new collaboration with MaSTherCell. We have been dosing patients with lifileucel in Europe for the treatment of metastatic melanoma and LN-145 for the treatment of cervical cancers. As part of our global development plan for our TIL product, we are initiating the IOV-COM-202 trial in Europe as well and have received approval from Medicines and Healthcare products Regulatory Agency (MHRA). This newly established relationship with MaSTherCell will add additional commercial-ready capacity to support our ongoing and upcoming trials,” said Dr. Maria Fardis, PhD, MBA, president and chief executive officer of Iovance Biotherapeutics.
 
“We are glad that Iovance called on our expertise to accelerate the development of their TIL products. By addressing the unmet needs for solid tumor treatment, the outcome of this project could represent an enormous hope for a considerable number of patients,” said Dr. Denis Bedoret, general manager of MaSTherCell. “MaSTherCell is really pleased to welcome Iovance in its new commercial plant for advanced cell therapy manufacturing.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics